EPAS1 and renal cell carcinoma: While the detection of VHL mutations alone has neither diagnostic nor prognostic significance, recent studies have shown that 49% of patients with VHL-associated RCC have achieved a substantial response to treatment with Belzutifan, a novel HIF-2α inhibitor [43–45].